Filing Flows › Orthopediatrics (KIDS) › Q3 2026 › vs Q3 2025
Orthopediatrics (KIDS) Q3 2026 vs Q3 2025 (year over year)
Orthopediatrics's revenue rose $11.4M (+19%) from $61.2M in Q3 2025 to $72.7M in Q3 2026. The biggest changes: Trauma and deformity +$8.5M (+19%); Scoliosis +$2.9M (+18%); Sports medicine/other +$20K (+2%).
Orthopediatrics, Q3 2026: revenue $72.7M (+19% year over year), operating margin -5.8%, net loss $5.9M, operating cash flow $4.5M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 2.2% | -5.6% | +7.8 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Trauma and deformity | $52.6M | $44.1M | $8.5M | +19% |
| Scoliosis | $19.2M | $16.3M | $2.9M | +18% |
| Sports medicine/other | $866K | $846K | $20K | +2% |
| Revenue | $72.7M | $61.2M | $11.4M | +19% |
| Income tax benefit | $109K | $125K | −$16K | -13% |
| Net loss | $5.9M | $11.8M | −$5.8M | -50% |
| Costs & expenses | $78.7M | $73.1M | $5.6M | +8% |
| Operating costs | $76.9M | $70.7M | $6.2M | +9% |
| Interest & other, net | $1.8M | $2.5M | −$656K | -27% |
| Cost of revenue | $18.7M | $16.0M | $2.7M | +17% |
| Research & development | $2.5M | $2.3M | $132K | +6% |
| Sales & marketing | $23.1M | $18.7M | $4.4M | +24% |
| General & admin | $32.0M | $29.2M | $2.9M | +10% |
| Other operating costs | $611K | $4.6M | −$4.0M | -87% |
| Operating cash sources | $10.4M | $11.2M | −$756K | -7% |
| Depreciation & amortization | $5.6M | $5.3M | $322K | +6% |
| Share-based compensation | $4.4M | $4.3M | $168K | +4% |
| Working capital & other | $396K | $1.6M | −$1.2M | -76% |
| Net loss absorbed | $5.9M | $11.8M | −$5.8M | -50% |
| Operating cash flow | $4.5M | −$581K | $5.1M | — |
| Free cash flow (OCF − capex) | $1.6M | −$3.4M | $5.0M | — |
| Capital expenditures | $2.9M | $2.8M | $72K | +3% |
Questions
How much did Orthopediatrics's revenue grow year over year in Q3 2026?
Orthopediatrics's revenue rose $11.4M (+19%) from $61.2M in Q3 2025 to $72.7M in Q3 2026.
What drove Orthopediatrics's revenue change in Q3 2026?
Trauma and deformity +$8.5M (+19%); Scoliosis +$2.9M (+18%); Sports medicine/other +$20K (+2%).